10-Q: Cardinal Health Reports Strong Q1 FY27 Results

Sentiment:

Quarterly Report


Cardinal Health announces a 5% revenue increase to $67.5 billion and a 27% rise in GAAP diluted EPS to $2.38 for its first quarter of fiscal year 2027.

Summary

  • Cardinal Health reported a 5% increase in total revenue for the first quarter of fiscal year 2027, reaching $67.5 billion.
  • GAAP operating earnings grew by 13% to $753 million, and GAAP diluted EPS increased by 27% to $2.38.
  • Non-GAAP operating earnings rose by 17% to $1.0 billion, with Non-GAAP diluted EPS up 28% to $3.26.
  • The Pharmaceutical and Specialty Solutions (Pharma) segment saw a 6% revenue increase to $62.6 billion and a 17% rise in segment profit.
  • The Global Medical Products and Distribution (GMPD) segment revenue remained flat at $3.2 billion, with a 28% decrease in segment profit.
  • The company maintained compliance with its net leverage ratio covenant.
  • Cash and equivalents increased to $5.3 billion.
  • The company made significant payments related to opioid litigation settlements.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and improved operating and diluted EPS, driven by robust performance in the Pharmaceutical and Specialty Solutions segment.

Positives

  • Revenue increased by 5% to $67.5 billion, driven by branded and specialty pharmaceutical sales.
  • GAAP operating earnings increased by 13% to $753 million.
  • GAAP diluted EPS increased by 27% to $2.38.
  • Non-GAAP operating earnings increased by 17% to $1.0 billion.
  • Non-GAAP diluted EPS increased by 28% to $3.26.
  • Pharma segment revenue grew 6% to $62.6 billion.
  • Pharma segment profit increased 17% to $783 million.
  • Gross margin increased 12% to $2.6 billion, with a 23 basis point improvement in gross margin rate.

Negatives

  • GMPD segment profit decreased by 28% to $33 million, primarily due to unfavorable distribution and foreign exchange impacts.
  • SG&A expenses increased by 9% to $1.6 billion, largely due to acquisitions and higher costs to support sales growth.
  • The company accrued $3.9 billion for opioid-related matters as of September 30, 2026, with significant future payments expected.
  • The company is facing potential tax liabilities related to IRS audits concerning net operating loss carrybacks and a business restructuring.

Risks

  • Potential adverse impacts from U.S. government policy initiatives on pharmaceutical manufacturer list prices, such as the Inflation Reduction Act.
  • Uncertainty regarding future impacts of administrative policies or actions on branded pharmaceutical product sales or profitability.
  • Potential increased costs or supply disruptions due to tariffs on imported branded pharmaceutical products and ingredients.
  • Unpredictable demand for GLP-1 medications and potential future demand growth moderation.
  • Potential changes in U.S. tariffs on generic pharmaceutical products in the future.
  • Uncertainty regarding the ultimate implementation of proposed tariffs on generic pharmaceutical products beginning in 2028 and 2029.
  • Higher than anticipated costs for fuel and transportation due to the conflict in Iran.
  • Potential adverse effects on financial results if increased costs from tariffs cannot be fully offset by price increases to customers.

Future Outlook

The company expects to continue to offset tariff impacts through cost optimization and price increases, though success is not guaranteed. Demand for GLP-1 medications is unpredictable, with growth moderation expected. The company anticipates returning portions of IEEPA tariff refunds to customers. Future annual payments for opioid litigation are expected through 2038.

Management Comments

  • "We are pleased to report a strong start to fiscal year 2027, with solid revenue growth and significant improvements in operating earnings and EPS."
  • "Our Pharmaceutical and Specialty Solutions segment continues to perform exceptionally well, driven by strong demand for branded and specialty pharmaceuticals."
  • "We remain committed to disciplined capital deployment, including share repurchases and dividends, while also managing our long-term liabilities."

Industry Context

StockSavvy.ai notes that Cardinal Health's performance in the Pharma segment aligns with broader trends of increasing demand for specialty pharmaceuticals, while the challenges in the GMPD segment reflect ongoing pressures from supply chain costs and foreign exchange fluctuations common in the healthcare distribution industry.

Comparison to Industry Standards

  • Cardinal Health's revenue growth of 5% in Q1 FY27 is a solid performance within the healthcare distribution sector, which has seen varied growth rates among peers due to differing product mixes and supply chain exposures.
  • The significant increase in GAAP and Non-GAAP Diluted EPS (27% and 28% respectively) suggests effective operational management and potentially favorable tax items, outperforming some competitors who have reported more modest EPS gains.
  • The decline in GMPD segment profit, despite flat revenue, is a concern that warrants monitoring, as many distributors are facing margin pressures from inflation and supply chain disruptions, though the extent of Cardinal Health's 28% decline is notable.
  • The company's proactive management of its credit facilities and commercial paper program, maintaining a leverage ratio below 4.00-to-1.00, is in line with prudent financial management observed across the industry.

Legal Proceedings

  • Opioid lawsuits and investigations: $3.9 billion accrued as of September 30, 2026, with ongoing payments and defense.
  • Insurance litigation with insurers regarding reimbursement for defense and indemnity costs for opioid lawsuits.
  • Department of Justice Civil Investigative Demand regarding potential violations of the Anti-Kickback Statute and False Claims Act.
  • IRS Notice of Proposed Adjustment challenging tax deductibility of self-insurance pre-tax losses and related carryback claims.
  • IRS Notice of Proposed Adjustment related to a restructuring that could create additional federal income tax liability.

Related Party Transactions

  • Red Oak Sourcing, LLC: A generic pharmaceutical sourcing venture with CVS Health Corporation, extended through June 2029.

Stakeholder Impact

  • Shareholders: Positive impact from increased EPS and ongoing share repurchase programs.
  • Customers: Potential for price increases due to tariffs, offset by efforts to mitigate costs. Benefits from improved Pharma segment performance.
  • Suppliers: Continued engagement through sourcing ventures like Red Oak Sourcing.
  • Creditors: Company remains in compliance with its net leverage ratio covenant for its revolving credit facility.

Next Steps

  • Continue to monitor and manage the impact of tariffs on financial results.
  • Pursue cost-savings and strategic initiatives.
  • Manage ongoing opioid litigation settlements and potential tax contingencies.
  • Continue to evaluate acquisitions and related reporting units for impairment indicators.

Key Dates

DateDescription
2025-11-03Completion of Solaris Health acquisition.
2026-07-01Record date for quarterly dividend paid on July 15, 2026.
2026-08-04Board of Directors approved quarterly dividend.
2026-08-07Entered into a consolidated $4.0 billion 5-year revolving credit facility.
2026-09-15Increased commercial paper program to $4.0 billion.
2026-09-18Conclusion of accelerated share repurchase (ASR) program.
2026-10-01Record date for quarterly dividend paid on October 15, 2026.
2026-11-05Filing date of the Form 10-Q.

Recommendation

hold

The company delivered a solid quarter with strong EPS growth and revenue increases, particularly in its Pharma segment. However, the persistent challenges in the GMPD segment, significant ongoing opioid litigation accruals, and potential tax liabilities warrant a cautious 'hold' rating until these headwinds are more clearly resolved or mitigated.

Keywords

Cardinal Health, Form 10-Q, Q1 Fiscal 2027, Pharmaceutical Distribution, Medical Products, Healthcare Services, Operating Earnings, Diluted EPS

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.